Insider Transactions in Q4 2022 at Nrx Pharmaceuticals, Inc. (NRXP)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2022
|
Seth Van Voorhees CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
30,000
+39.3%
|
$30,000
$1.1 P/Share
|
|
Dec 16
2022
|
Stephen H Willard CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$50,000
$1.17 P/Share
|
|
Dec 07
2022
|
Jonathan C Javitt Chief Scientist |
SELL
Open market or private sale
|
Indirect |
400,000
-3.01%
|
$400,000
$1.0 P/Share
|
|
Nov 30
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,441
-0.09%
|
$8,441
$1.5 P/Share
|
|
Nov 29
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,730
-0.14%
|
$13,730
$1.5 P/Share
|
|
Nov 28
2022
|
Patrick John Flynn |
BUY
Open market or private purchase
|
Direct |
1,750
+50.0%
|
$1,750
$1.25 P/Share
|
|
Nov 28
2022
|
Patrick John Flynn |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.04%
|
$10,000
$1.25 P/Share
|
|
Nov 25
2022
|
Seth Van Voorhees CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Indirect |
16,337
+28.69%
|
$16,337
$1.11 P/Share
|
|
Nov 18
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
40,408
+7.48%
|
$40,408
$1.1 P/Share
|
|
Nov 17
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
171,780
+27.21%
|
$171,780
$1.08 P/Share
|
|
Nov 17
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,018
-0.34%
|
$33,018
$1.05 P/Share
|
|
Nov 16
2022
|
Chaim Hurvitz |
BUY
Open market or private purchase
|
Direct |
287,812
+50.0%
|
$0
$0.99 P/Share
|
|
Nov 16
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
133,719
-1.36%
|
$133,719
$1.02 P/Share
|
|
Nov 11
2022
|
Daniel C. Javitt > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,200
-0.5%
|
$49,200
$1.01 P/Share
|